ESH MDS 2021 | Prognostic factors and mutations in MDS
Felicitas Thol
• 22 Jan 2021
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the use of prognostic scoring systems in the treatment of myelodysplastic syndromes (MDS) at ESH MDS 2021. Dr Thol also outlines the use of molecular profiling and the need to consider mutations, in particular the TP53 mutation, to select more targeted therapies. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
